NEW YORK (AP) _ TG Therapeutics Inc. (TGTX) on Friday reported a loss of $35.2 million in its first quarter.
On a per-share basis, the New York-based company said it had a loss of 43 cents.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 47 cents per share.
The biopharmaceutical company posted revenue of $38,000 in the period, meeting Street forecasts.
TG Therapeutics shares have risen 98% since the beginning of the year. The stock has declined 37% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TGTX at https://www.zacks.com/ap/TGTX